Research output per year
Research output per year
Fingerprint
Dive into the research topics where Hyuncheol Chung is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 12 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Research output
-
Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis
Park, S., Nam, C. M., Kim, S. G., Mun, J. E., Rha, S. Y. & Chung, H. C., 2021 Feb, In: European Journal of Cancer. 144, p. 49-60 12 p.Research output: Contribution to journal › Review article › peer-review
-
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Chung, H. C., Bang, Y. J., S Fuchs, C., Qin, S. K., Satoh, T., Shitara, K., Tabernero, J., Cutsem, E. V., Alsina, M., Cao, Z. A., Lu, J., Bhagia, P., Shih, C. S. & Janjigian, Y. Y., 2021 Feb, In: Future Oncology. 17, 5, p. 491-501 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer
Bae, H. J., Kang, S. K., Kwon, W. S., Jeong, I., Park, S., Kim, T. S., Kim, K. H., Kim, H., Jeong, H. C., Chung, H. C. & Rha, S. Y., 2021 Jan, In: Biochemical Pharmacology. 183, 114320.Research output: Contribution to journal › Article › peer-review
-
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Chen, L. T., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., Chen, J. S., Muro, K., Kang, W. K., Yeh, K. H., Yoshikawa, T., Oh, S. C., Bai, L. Y., Tamura, T., Lee, K. W., Hamamoto, Y., Kim, J. G., Chin, K., Oh, D. Y., Minashi, K. & 5 others, , 2020 May 1, In: Gastric Cancer. 23, 3, p. 510-519 10 p.Research output: Contribution to journal › Article › peer-review
Open Access26 Citations (Scopus) -
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., Italiano, A., Kao, S., Piha-Paul, S. A., Delord, J. P., McWilliams, R. R., Fabrizio, D. A., Aurora-Garg, D., Xu, L., Jin, F., Norwood, K. & 1 others, , 2020 Oct, In: The Lancet Oncology. 21, 10, p. 1353-1365 13 p.Research output: Contribution to journal › Article › peer-review
28 Citations (Scopus)